Insulin degludec

Insulin degludec
An insulin degludec hexamer. A chains are chartreuse, B chains are tan, and the central zinc atom is teal. From PDB: 4AKJ​.
Clinical data
Trade namesTresiba
AHFS/Drugs.comMonograph
MedlinePlusa615055
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Subcutaneous
ATC code
Legal status
Legal status
Pharmacokinetic data
Onset of action30–90 minutes
Duration of action≤ 42 hours
Identifiers
  • B29N(ε)-ω-carboxypentadecanoyl-γ-L-glutamyl desB30 human insulin
CAS Number
PubChem SID
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC274H411N65O81S6
Molar mass6104.04 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[7] It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,[8][9][10] that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.

Insulin degludec is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29.

It is included on the World Health Organization's List of Essential Medicines[11] as an equivalent to insulin glargine. In 2022, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[12][13]

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
  2. ^ https://www.tga.gov.au/resources/publication/scheduling-decisions-final/scheduling-delegates-final-decisions-january-2018/111-insulin-deglude [bare URL]
  3. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
  4. ^ "Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
  5. ^ "Tresiba- insulin degludec injection, solution". DailyMed. 1 July 2022. Archived from the original on 7 July 2022. Retrieved 11 February 2024.
  6. ^ "Tresiba EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 22 January 2021. Retrieved 15 January 2021.
  7. ^ Cite error: The named reference CHMP2012 was invoked but never defined (see the help page).
  8. ^ Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–299. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.
  9. ^ Haahr H, Heise T (September 2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.
  10. ^ "Tresiba Summary of product characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 4 March 2016. Retrieved 29 September 2014.
  11. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  12. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  13. ^ "Insulin Degludec Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.